<i>BRCA1</i> and <i>2</i> mutations are known to be associated with breast cancer, and olaparib, a poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor, has been shown to be effective in cells carrying these mutations in some studies. This evidence concerns the gene BRCA1 and breast carcinoma.